KGEN-001 | CAR-T Research for Glioblastoma
KGEN-001 is KiraGen Bio’s preclinical CAR-T program for recurrent glioblastoma, combining healthy-donor cells, dual targeting, and multiplex base editing.

KiraGen Bio engineers healthy-donor CAR-T cell therapies for solid tumors whose cells resist tumor shutdown signals with programmable durability.
kiragenbio.comCrawled Nov 3, 2026
KGEN-001 is KiraGen Bio’s preclinical CAR-T program for recurrent glioblastoma, combining healthy-donor cells, dual targeting, and multiplex base editing.
KiraLOGIC develops and tests gene-editing combinations designed to overcome tumor suppression, using experimental results to guide selection.
Co-founder and CEO Aaron Edwards wrote about the relationship between science, business, and biotechnology development following his internship at Eli Lilly.
The former Poseida cell-therapy CSO brings experience in allogeneic CAR-T engineering, platform development, and clinical translation to KiraGen's scientific advisory team.
KiraGen is evaluating multiplex-engineered CAR-T cells in patient-derived tumor samples and brain-tumor models in mice.
KiraGen highlighted co-founder and CSO Ryan Murray's research on coordinated engineering against rejection and overlapping tumor suppression.
KiraGen's Head of Immunoinformatics contributed to three recent studies spanning tumor biology, single-cell analysis, and the reliability of biomedical machine learning.
KiraGen moved into Tufts Launchpad | BioLabs in downtown Boston, expanding its access to flexible laboratory infrastructure, shared resources, and a collaborative biotech community.
Additional provisional filings related to engineered immune cells expand KiraGen's developing intellectual property portfolio around its platform and product programs.
Co-founder and CEO Aaron Edwards presented KiraGen's approach to building allogeneic CAR-T cells with intrinsic resistance to multiple suppressive pathways during an invited ASGCT symposium.
Co-founder and CEO Aaron Edwards will present KiraGen's approach to multiplex engineering for durable CAR-T activity in glioblastoma on September 15 at the CAR-TCR Summit in Boston.
The grant supports testing in patient-derived glioblastoma brain-tumor models, with a focus on sustained tumor control.
Company updates, scientific perspectives, publications, and milestones from KiraGen Bio.
KiraGen is built by cell-therapy operators with experience across multiplex gene editing, tumor biology, computation, manufacturing, and clinical translation.
How KiraGen uses multiplex base editing to protect CAR-T cells from multiple suppressive signals in solid tumors.
Contact KiraGen Bio about partnerships, investment, research, media, or general company inquiries.
KiraGen Bio develops multiplex-edited CAR-T therapies designed to resist suppressive tumor signals, starting with recurrent glioblastoma.
How information submitted through the KiraGen Bio website is used for inquiries and email updates.
The **National Brain Tumor Society** awards KiraGen Bio a grant to test its **KGEN-001 CAR-T cell therapy** in glioblastoma models using patient-derived tumors implanted in laboratory animals. The study evaluates the engineered cells’ potential in preclinical settings. KiraGen Bio develops next-generation CAR-T therapies for brain cancers.
KiraGen appoints Devon Shedlock, PhD, as scientific advisor. Shedlock previously served as Chief Scientific Officer for Cell Therapies at Poseida Therapeutics and was the company’s first employee. His expertise in cell therapies brings specialized insights to KiraGen’s research and development efforts.
The Musella Foundation awards KiraGen a $50,000 grant to advance research on patient-derived glioblastoma (GBM) models. The funding supports KiraGen’s efforts in developing therapies targeting this aggressive brain tumor type. KiraGen focuses on leveraging patient-specific samples to improve treatment precision.
The **Yuvaan Tiwari Foundation** invests in **KiraGen Bio** to advance its research on durable cell-therapy treatments for brain cancers. The funding supports the company’s focus on innovative therapeutic approaches targeting aggressive neurological diseases. KiraGen Bio develops cell-based solutions aimed at improving patient outcomes in oncology.
KiraGen receives a $50,000 grant from The Cure Starts Now to advance CAR-T cell therapy research targeting diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma. The funding supports translational research aimed at developing treatments for these aggressive pediatric brain tumors. KiraGen focuses on gene-editing and cell therapy approaches for rare and hard-to-treat cancers.
ZAKA VC backs KiraGen Bio, a biotech startup creating multiplex gene-edited CAR-T cell therapies targeting solid tumors. The therapies aim to address limitations in current treatments by improving efficacy and overcoming tumor resistance mechanisms. KiraGen Bio focuses on advancing precision oncology solutions for previously hard-to-treat cancers.